Foghorn Therapeutics' revenue estimates downgraded by analys...
Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Analysts Just Slashed This Year's Estimates
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3239Followers
0Following
8004Visitors
Follow